Gladstone Institutional Advisory LLC Acquires 26,900 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Gladstone Institutional Advisory LLC raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 47.7% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 83,300 shares of the biotechnology company's stock after purchasing an additional 26,900 shares during the period. Gladstone Institutional Advisory LLC owned approximately 0.09% of Sarepta Therapeutics worth $10,403,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in SRPT. Riggs Asset Managment Co. Inc. boosted its stake in shares of Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company's stock worth $29,000 after buying an additional 125 shares during the last quarter. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $31,000. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics in the 1st quarter worth approximately $32,000. Nkcfo LLC purchased a new position in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $43,000. Finally, UMB Bank n.a. boosted its stake in shares of Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock worth $48,000 after buying an additional 197 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Activity

In other news, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael Andrew Chambers purchased 37,038 shares of the firm's stock in a transaction that occurred on Friday, August 16th. The stock was bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares of the company's stock, valued at $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 7.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on SRPT shares. Citigroup cut their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating on the stock in a research note on Thursday, August 8th. UBS Group lifted their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a "buy" rating in a report on Tuesday, September 17th. Barclays lowered their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. William Blair raised shares of Sarepta Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $152.00 price target on shares of Sarepta Therapeutics in a report on Friday, September 20th. Two investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $182.95.

Sarepta Therapeutics Trading Down 2.2 %

NASDAQ SRPT traded down $2.71 during trading on Friday, hitting $123.29. 1,141,422 shares of the company's stock traded hands, compared to its average volume of 1,230,011. The stock has a fifty day moving average of $128.07 and a two-hundred day moving average of $132.57. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics, Inc. has a 12-month low of $75.69 and a 12-month high of $173.25. The firm has a market cap of $11.76 billion, a P/E ratio of 277.03 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company's quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.27) earnings per share. As a group, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 1.48 EPS for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.